
Development of a Precision Medicine-based Diagnostic Tool for Membranous NephropathyAward last edited on: 11/17/2023
Sponsored Program
STTRAwarding Agency
NIH : NIDDKTotal Award Amount
$2,197,042Award Phase
2Solicitation Topic Code
847Principal Investigator
Christopher P LarsenCompany Information
Nephropathology Associates PLC
10810 Executive Center Drive Suite 100
Little Rock, AR 72211
Little Rock, AR 72211
(866) 736-2529 |
support@arkanalabs.com |
www.arkanalabs.com |
Research Institution
University of Arkansas
Phase I
Contract Number: 1R41DK130702-01Start Date: 7/15/2021 Completed: 6/30/2022
Phase I year
2021Phase I Amount
$247,778Project Terms:
Accounting ; Algorithms ; Antibodies ; Antigen-Antibody Complex ; Immune Complex ; Antigens ; immunogen ; Archives ; Autoantibodies ; autoimmune antibody ; autoreactive antibody ; self reactive antibody ; Autoantigens ; Autologous Antigens ; Self-Antigens ; Autoimmune Responses ; Biopsy ; Statistical Data Interpretation ; Statistical Data Analyses ; Statistical Data Analysis ; statistical analysis ; Diagnosis ; Disease ; Disorder ; Explosion ; Freezing ; Future ; Patient Care ; Patient Care Delivery ; Membranous Glomerulonephritis ; Extramembranous Glomerulopathy ; Membranous Glomerulonephropathy ; Membranous Glomerulopathy ; Membranous Nephropathy ; Goals ; Immunoglobulin G ; 7S Gamma Globulin ; IgG ; Immunoassay ; Kidney ; Kidney Urinary System ; renal ; Kidney Diseases ; Nephropathy ; Renal Disease ; kidney disorder ; renal disorder ; Laboratories ; Literature ; Lupus Nephritis ; Lupus Glomerulonephritis ; Methods ; United States National Institutes of Health ; NIH ; National Institutes of Health ; Nephritis ; Pathology ; Patients ; Peptides ; Proteins ; Proteinuria ; Publishing ; Resources ; Research Resources ; Mass Spectrum Analysis ; Mass Photometry/Spectrum Analysis ; Mass Spectrometry ; Mass Spectroscopy ; Mass Spectrum ; Mass Spectrum Analyses ; Testing ; Time ; Tissue Extracts ; Tissues ; Body Tissues ; G-substrate ; cerebellum protein substrate for cGMP dependent protein kinase ; protein G ; Measures ; Data Set ; Dataset ; analytical method ; base ; Phase ; Pythons ; Evaluation ; Training ; Glomerular Capillary ; Databases ; Data Bases ; data base ; Funding ; clinical Diagnosis ; Morphology ; Deposit ; Deposition ; tool ; Diagnostic ; machine learned ; Machine Learning ; Immunes ; Immune ; Techniques ; early detection ; Early Diagnosis ; rapid diagnosis ; cohort ; Biopsy Sample ; Biopsy Specimen ; novel ; Reporting ; Modeling ; Sampling ; Proteomics ; Pathogenicity ; Visceral Epithelial Cell ; glomerular visceral epithelial cell ; podocyte ; Incubated ; Data ; Reproducibility ; Flare ; Immunologics ; Immunochemical Immunologic ; Immunologic ; Immunological ; Immunologically ; Monitor ; Process ; Development ; developmental ; cost ; predictive modeling ; computer based prediction ; prediction model ; data acquisition ; treatment response ; response to treatment ; therapeutic response ; Biological Markers ; bio-markers ; biologic marker ; biomarker ; clinical practice ; disease diagnosis ; precision medicine ; precision-based medicine ; clinical diagnostics ; classification algorithm ; kidney biopsy ; renal biopsy ; data pipeline ; data analysis pipeline ; data processing pipeline ; learning classifier ; feature selection ; Autoimmune ; pathogenic autoantibodies ; Prognosis ;
Phase II
Contract Number: 2R44DK130702-02Start Date: 7/15/2021 Completed: 5/31/2024
Phase II year
2022(last award dollars: 2023)
Phase II Amount
$1,949,264Public Health Relevance Statement:
Project Narrative Membranous nephropathy (MN) is due to autoantibodies against a range of endogenous proteins and leads to kidney failure in an alarming one-third of patients. Classifying a patient's disease by autoantigen can lead to dramatic improvements in prognosis through more personalized treatment as well as reveal underlying and life-threatening comorbidities such as cancer and specific autoimmune diseases. Arkana Laboratories has developed an MS based workflow capable of identifying autoantigens responsible for MN in a given patient with approximately 95% accuracy. Here, we will translate the assay and analytical workflow to the company's CLIA- certified laboratory prior to commercial launch, providing clinicians with a new approach to MN based on specific molecular etiologies to support improved, personalized treatment.
Project Terms: